



9 November 2006

RESOLUTIONS PASSED AT ANNUAL GENERAL MEETING

At the Annual General Meeting of Biomedical company, **Tissue Therapies Limited** (ASX: TIS) held on 9 November 2006 the following resolutions were passed by a show of hands:

2. Election of David Gardiner

'That David George Gardiner, who retires in accordance with Rule 16.1 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'

3. Election of Gregory Baynton

'That Gregory Baynton who retires in accordance with Rule 16.1 of the Company's Constitution, and being eligible, be re-elected as a Director of the Company.'

4. Directors' Remuneration Report

'That the section of the Directors' Report dealing with the remuneration of the Company's Directors, Company Secretary and Senior Executives ('Remuneration Report') be adopted.'

5. Ratification and Approval of Previous Allotment and Issue of Shares

'That for the purposes of Listing Rule 7.4 and for all other purposes, the prior issue and allotment of 2,315,500 Shares at an issue price of \$0.70 under a share placement made on 23 November 2005 be ratified.'

Summary of Proxy Votes Lodged

Resolution Name	For	At Discretion of Proxy Holder	Against	Abstain	Invalid
2	1,789,131	1,512,597	0	69,500	0
3	1,284,131	1,512,597	5,000	569,500	0
4	1,749,686	1,547,598	50,586	23,358	0
5	1,112,709	1,334,536	55,991	99,073	768,919

ENDS

Further information or for an interview:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: (07) 3221 0140

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a platform technology developed by tissue engineering experts at Queensland University of Technology for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration and cell culture.

Based on its VitroGro® platform technology, Tissue Therapies is developing more effective medical treatments for wounds and burns, integration of orthopaedic and medical implants, and other applications such as cosmeceuticals.

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com